磷酸二酯酶5抑制剂研究进展  

Recent research progress in inhibitors of phosphodiesterase type 5, a new kind of anti-male erectile dysfunction agent

作　　者：王佳宁[1] 吴松[1] 

机构地区：[1]中国医学科学院中国协和医科大学药物研究所开发室,北京100050

出　　处：《中国新药杂志》2002年第7期523-527,共5页Chinese Journal of New Drugs

摘　　要：男性勃起功能障碍 (ED) ,是临床上较为常见的一种性功能障碍疾病。磷酸二酯酶 5 (PDE5 )是存在于平滑肌、血小板等组织中一种有特定结构和功能的磷酸二酯酶亚型。口服PDE5抑制剂使环磷酸鸟苷酸水平升高 ,促使血管平滑肌扩张 ,能达到治疗男性ED的作用。目前除了西地那非以外 ,还有一些结构不同的化合物具有PED5抑制作用 ,他们有可能成为更具疗效及选择性的ED治疗药物。Male erectile dysfunction (ED) is a common clinical sexual dysfunction.Phosphodiesterases type 5(PDE5) is one of phosphodiesterases families that are particularly abundant in smooth muscle and blood platelet.Taking the PDE5 inhibitors raises the level of cGMP,induces dilation of smooth muscle,so that cures the male ED.Besides the sildenafil,there are also some other kinds of compounds that can inhibit PDE5. Maybe they will become selective and effective anti impotence drugs.In this paper,research progress in PDE5 inhibitors was reviewed.

关 键 词：男性勃起功能障碍 磷酸二酯酶5 先导化合物 

分 类 号：R977.3[医药卫生—药品]